Alkermes plc has reported positive findings from a phase 1b study of ALKS 2680, an oral orexin 2 receptor agonist, in patients with narcolepsy type 2 (NT2) and idiopathic hypersomnia (IH).

Medicenna Therapeutics Corp. has reported positive interim results from its Phase 1/2 ABILITY-1 study of MDNA11, a long-acting interleukin-2 (IL-2) super-agonist.

In a recent clinical trial, 20 patients suffering from relapsed or refractory B-cell non-Hodgkin lymphoma (B-NHL) were administered a combination treatment of evorpacept, rituximab, and lenalidomide, commonly referred to as the "R2" regimen.

Vanqua Bio, a clinical-stage biopharmaceutical company, has dosed the first patient in a Phase 1 clinical trial for VQ-101, an oral, brain-penetrating small molecule allosteric activator of glucocerebrosidase (GCase).

Corvus Pharmaceuticals, a biopharmaceutical firm, has launched a Phase 1 clinical trial for soquelitinib, a selective ITK inhibitor, to treat moderate to severe atopic dermatitis.

Initial clinical trials for STK-012, an innovative engineered cytokine by Synthekine Inc., have shown promising results in treating advanced solid tumors.

BioCity Biopharma has received approval from the FDA to commence a Phase 1 clinical trial for BC2027, marking it as the company's second innovative antibody drug conjugate (ADC) to reach this stage.

ViGeneron GmbH, a clinical-stage gene therapy firm, has initiated a Phase Ib clinical trial for VG901, a novel treatment for retinitis pigmentosa (RP) caused by CNGA1 gene mutations.

In a recent clinical study, two patients with advanced cancers, one with melanoma and the other with pancreatic cancer, experienced a complete disappearance of their targeted tumors.

Monopar Therapeutics, a biopharmaceutical firm listed on Nasdaq as MNPR, has initiated a Phase 1 clinical trial for a novel imaging agent, MNPR-101-Zr.

A recent study presented at the 2024 AACR highlighted the potential of SKB264, an antibody-drug conjugate (ADC) developed by Merck and Kelun-Biotech, in treating gastric and gastroesophageal junction cancers.

Boundless Bio, a clinical-stage oncology firm, has initiated a Phase 1/2 clinical trial for BBI-825, an innovative oral inhibitor of ribonucleotide reductase (RNR), as part of the STARMAP study.